RPAM
APGE

Rhenman & Partners Asset Management’s Apogee Therapeutics APGE Stock Holding History

Rhenman & Partners Asset Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-75,000
Closed -$6.31M – 101
2026
Q1 		$6.31M Buy
+75,000
New +$5.45M 0.78% 51

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Rhenman & Partners Asset Management's APGE Position: Q2 2026 in Review

Rhenman & Partners Asset Management sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 75,000 shares — an estimated $6.31M sold.

Rhenman & Partners Asset Management first reported a position in APGE in Q1 2026 and held it in 1 quarter. The position peaked at $6.31M in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Rhenman & Partners Asset Management reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 75,000 Apogee Therapeutics shares in Q2 2026, an estimated $6.31M.
  • Rhenman & Partners Asset Management first reported a position in Apogee Therapeutics in Q1 2026 and held it in 1 quarter.
  • Rhenman & Partners Asset Management's Apogee Therapeutics position peaked at $6.31M in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.